Related Experiment Video
Updated: Apr 11, 2026
07:06
Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies
Published on: January 10, 2025
1.4K
Effects of oral hypoglycemic agents on platelet function.
Athanasia Papazafiropoulou1, Nikolaos Papanas2, Stavros Pappas3
1Diabetes Centre, Third Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Greece; Diabetes Centre, First Department of Internal Medicine, Tzaneio General Hospital of Piraeus, Piraeus, Greece.
Journal of Diabetes and Its Complications
|June 1, 2015
Summary
Oral hypoglycemic agents (OHAs) can favorably impact platelet function, potentially reducing cardiovascular risk in type 2 diabetes. More research is needed on newer therapies and their effects on platelet aggregation.
Area of Science:
- Endocrinology
- Hematology
- Pharmacology
Background:
- Platelet dysfunction is implicated in macrovascular complications of diabetes.
- Oral hypoglycemic agents (OHAs) are widely used for type 2 diabetes management.
- Understanding OHA effects on platelet function is crucial for cardiovascular risk reduction.
Purpose of the Study:
- To review the existing evidence on the effects of oral hypoglycemic agents (OHAs) on platelet function.
- To assess the impact of traditional and newer OHAs on platelet aggregation and related parameters.
- To identify knowledge gaps regarding OHA effects on platelet function in type 2 diabetes.
Main Methods:
- Systematic review of in vivo and in vitro studies.
- Analysis of data on various classes of oral hypoglycemic agents.
- Evaluation of studies investigating platelet aggregation and function.
Main Results:
- Most traditional OHAs, including metformin, sulfonylureas, glitazones, and acarbose, show beneficial effects on platelet function.
- Limited evidence exists for the newer incretin-based therapies, with sitagliptin demonstrating a positive effect on platelet aggregation.
- Data on the broader impact of newer oral hypoglycemic agents on platelet function remains scarce.
Conclusions:
- Traditional oral hypoglycemic agents appear to exert favorable effects on platelet function.
- Further in vivo and in vitro research is necessary to fully elucidate the impact of various OHAs, especially newer agents, on platelet function.
- Potential benefits of OHAs on platelet function may contribute to reducing cardiovascular risk in patients with type 2 diabetes mellitus.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
901
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
901
01:06Oral Hypoglycemic Agents: Glinides
981
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
981
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
981
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
981
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K